SG11201913014YA - Dihydro-pyrrolo-pyridine derivatives - Google Patents
Dihydro-pyrrolo-pyridine derivativesInfo
- Publication number
- SG11201913014YA SG11201913014YA SG11201913014YA SG11201913014YA SG11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolo
- dihydro
- pyridine derivatives
- pyridine
- derivatives
- Prior art date
Links
- JKWQHCSGMTWRIQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NCCC2=N1 JKWQHCSGMTWRIQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523306P | 2017-06-22 | 2017-06-22 | |
PCT/IB2018/054390 WO2018234953A1 (fr) | 2017-06-22 | 2018-06-14 | Dérivés de dihydro-pyrrolo-pyridine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201913014YA true SG11201913014YA (en) | 2020-01-30 |
Family
ID=62981279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201913014YA SG11201913014YA (en) | 2017-06-22 | 2018-06-14 | Dihydro-pyrrolo-pyridine derivatives |
Country Status (19)
Country | Link |
---|---|
US (1) | US11198692B2 (fr) |
EP (1) | EP3642202B1 (fr) |
JP (1) | JP7263266B2 (fr) |
KR (1) | KR20200013783A (fr) |
CN (1) | CN110944998B (fr) |
AU (1) | AU2018287787A1 (fr) |
BR (1) | BR112019026955A2 (fr) |
CA (1) | CA3066986A1 (fr) |
DK (1) | DK3642202T3 (fr) |
ES (1) | ES2937236T3 (fr) |
FI (1) | FI3642202T3 (fr) |
HU (1) | HUE060914T2 (fr) |
IL (1) | IL271290B2 (fr) |
MX (1) | MX2019015371A (fr) |
PL (1) | PL3642202T3 (fr) |
PT (1) | PT3642202T (fr) |
SG (1) | SG11201913014YA (fr) |
TW (1) | TWI680128B (fr) |
WO (1) | WO2018234953A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
WO2024088408A1 (fr) * | 2022-10-28 | 2024-05-02 | 纽欧申医药(上海)有限公司 | Composé hétérocyclique contenant de l'azote, sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son utilisation |
WO2024130062A1 (fr) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Composés tétrahydropyrrolo-pyridinone substitués et leur utilisation dans le traitement d'états pathologiques |
WO2024130066A1 (fr) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Composés tétrahydropyrrolo-pyridinone substitués et leur utilisation dans le traitement de problèmes de santé |
WO2024130065A1 (fr) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Composés de dihydropyrrolo[3,4-d]pyrimidine substitués et leur utilisation dans le traitement d'états pathologiques |
WO2024130064A1 (fr) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Composés tétrahydropyrrolo-pyridinone substitués et leur utilisation dans le traitement d'états pathologiques |
WO2024130068A1 (fr) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Composés de dihydropyrrolo[3,4-d]pyrimidine substitués et leur utilisation dans le traitement d'états pathologiques |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123612A (en) * | 1964-03-03 | Z-acylated z | ||
US2767191A (en) * | 1953-12-31 | 1956-10-16 | American Cyanamid Co | Dihydropyrrolo-pyridines |
EP0683234B2 (fr) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
DK0994728T3 (da) | 1997-04-09 | 2008-12-01 | Intellect Neurosciences Inc | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf |
US6929808B2 (en) | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP2000109481A (ja) * | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
CZ2008595A3 (cs) | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
WO2003016466A2 (fr) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anticorps anti-$g(a)$g(b) |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
EP1633786A4 (fr) | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2004110996A1 (fr) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Antagoniste de nk1 |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
EP1720847A1 (fr) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Modulateurs du recepteur de l'histamine-3 |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (fr) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine |
US7807165B2 (en) | 2004-07-30 | 2010-10-05 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
CN100577666C (zh) | 2004-10-25 | 2010-01-06 | 伊莱利利公司 | 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类 |
WO2006069081A2 (fr) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | Utilisation d'anticorps anti-a$g(b) pour le traitement d'un traumatisme cerebral |
RS51204B (sr) * | 2005-02-07 | 2010-12-31 | F. Hoffmann-La Roche Ag. | Heterociklični supstituisani fenil metanoni kao inhibitori glicin transportera 1 |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
AU2006245416B2 (en) | 2005-05-12 | 2012-02-23 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
CA2608672A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones |
CA2603830A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | Pyridine [2,3-b] pyrazinones |
WO2006126083A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Composes de pyridine [3 , 4-b] pyrazinones utilises comme inhibiteurs de pde-5 |
ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
WO2007063385A2 (fr) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques |
WO2007069053A1 (fr) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Antagonistes benzimidazoliques du récepteur h-3 |
WO2007088450A2 (fr) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagoniste du récepteur h-3 |
WO2007088462A1 (fr) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Antagonistes du récepteur du h-3 à base de spirochromane |
WO2007099423A1 (fr) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3 |
US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
WO2007122466A1 (fr) | 2006-04-21 | 2007-11-01 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
WO2007138431A2 (fr) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Antagonistes de l'éther histamine-3 azabicyclique |
NZ577951A (en) | 2007-01-22 | 2012-02-24 | Pfizer Prod Inc | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
US20100273772A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
EP2624697B1 (fr) | 2010-10-04 | 2015-11-25 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de dihydrobenzoquinazolinone |
JP6117104B2 (ja) | 2010-11-15 | 2017-04-19 | アッヴィ・インコーポレイテッド | Namptおよびrock阻害薬 |
EP3321257A1 (fr) | 2012-02-23 | 2018-05-16 | Vanderbilt University | Analogues de 5-aminothiéno[2,3-c]pyridazine-6-carboxamide substitués en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
WO2014035829A1 (fr) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Analogues de 3-aminothiéno[2,3-c]pyridine-2-carboxamide substitués utilisés comme modulateurs allostériques positifs |
WO2015027204A1 (fr) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Analogues de thiéno[2,3-b]pyridine-2-carboxamide substitués à utiliser en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
EP3036233A1 (fr) | 2013-08-23 | 2016-06-29 | Vanderbilt University | Analogues de thiéno[2,3-c]pyridazine-6-carboxamide substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
DK3478679T3 (da) * | 2016-07-01 | 2021-06-21 | Pfizer | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme |
GB201616839D0 (en) * | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
-
2018
- 2018-06-14 FI FIEP18743584.7T patent/FI3642202T3/fi active
- 2018-06-14 KR KR1020207001865A patent/KR20200013783A/ko unknown
- 2018-06-14 MX MX2019015371A patent/MX2019015371A/es unknown
- 2018-06-14 CN CN201880049365.XA patent/CN110944998B/zh active Active
- 2018-06-14 SG SG11201913014YA patent/SG11201913014YA/en unknown
- 2018-06-14 ES ES18743584T patent/ES2937236T3/es active Active
- 2018-06-14 CA CA3066986A patent/CA3066986A1/fr active Pending
- 2018-06-14 US US16/625,202 patent/US11198692B2/en active Active
- 2018-06-14 DK DK18743584.7T patent/DK3642202T3/da active
- 2018-06-14 HU HUE18743584A patent/HUE060914T2/hu unknown
- 2018-06-14 AU AU2018287787A patent/AU2018287787A1/en not_active Abandoned
- 2018-06-14 JP JP2019570547A patent/JP7263266B2/ja active Active
- 2018-06-14 PL PL18743584.7T patent/PL3642202T3/pl unknown
- 2018-06-14 EP EP18743584.7A patent/EP3642202B1/fr active Active
- 2018-06-14 WO PCT/IB2018/054390 patent/WO2018234953A1/fr unknown
- 2018-06-14 IL IL271290A patent/IL271290B2/en unknown
- 2018-06-14 PT PT187435847T patent/PT3642202T/pt unknown
- 2018-06-14 BR BR112019026955-0A patent/BR112019026955A2/pt not_active Application Discontinuation
- 2018-06-19 TW TW107120944A patent/TWI680128B/zh active
Also Published As
Publication number | Publication date |
---|---|
ES2937236T3 (es) | 2023-03-27 |
PT3642202T (pt) | 2023-02-02 |
TWI680128B (zh) | 2019-12-21 |
EP3642202A1 (fr) | 2020-04-29 |
AU2018287787A1 (en) | 2020-01-16 |
DK3642202T3 (da) | 2023-01-30 |
HUE060914T2 (hu) | 2023-04-28 |
BR112019026955A2 (pt) | 2020-06-30 |
US11198692B2 (en) | 2021-12-14 |
IL271290A (en) | 2020-01-30 |
CN110944998A (zh) | 2020-03-31 |
TW201920166A (zh) | 2019-06-01 |
FI3642202T3 (fi) | 2023-03-01 |
IL271290B1 (en) | 2023-07-01 |
EP3642202B1 (fr) | 2022-11-02 |
KR20200013783A (ko) | 2020-02-07 |
WO2018234953A1 (fr) | 2018-12-27 |
US20200262833A1 (en) | 2020-08-20 |
MX2019015371A (es) | 2020-07-20 |
CN110944998B (zh) | 2022-08-16 |
PL3642202T3 (pl) | 2023-03-13 |
IL271290B2 (en) | 2023-11-01 |
CA3066986A1 (fr) | 2018-12-27 |
JP2020524687A (ja) | 2020-08-20 |
JP7263266B2 (ja) | 2023-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255045A1 (zh) | 取代的氧代吡啶衍生物 | |
IL271607A (en) | New azaquinoline histories | |
IL253381A0 (en) | History of h9-pyrrolo-dipyridine | |
IL269038A (en) | Cryotherapy | |
IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
AU201714106S (en) | Mandoline | |
SG11202002846TA (en) | Message-credentialed blockchains | |
DK3401557T3 (en) | Træskrue | |
LT3796975T (lt) | Sulfonilaminobenzamido dariniai | |
IL279938A (en) | History of spirochroman | |
IL251005B (en) | Pyrido-oxazinone derivatives | |
PL3770162T3 (pl) | Pochodne dihydrochromenu | |
GB201702641D0 (en) | Easpagnolette | |
DK3351149T3 (en) | Syltetøjsfontæne | |
GB201806948D0 (en) | Derivatives | |
GB201716028D0 (en) | Hummocks | |
AU201715236S (en) | Striplight | |
GB201713879D0 (en) | Hwbh-3 | |
AP00994S1 (en) | Autorickshaw | |
GB201710051D0 (en) | Clipmedia | |
GB201709690D0 (en) | Pi-safe | |
GB201706984D0 (en) | Headware | |
GB201704353D0 (en) | Superswoosher | |
GB201703458D0 (en) | Seismocardiography | |
GB201702219D0 (en) | Roadplate |